ER Positive Braest Cancer and others By Govind Babu
Session 2 : ER Positive Braest Cancer and others
Ramesh Nimmagadda, N K Warrier
EndoPredict(EPclin) score for estimating residual distant (DR) risk in ER+/HER2-breast-cancer(br ca) patients treated with 5 year adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score(RS)
Author: DowSett M
"BEST ABSTRACT: Prospective trail of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node negative breast cancer: Result of the TAILORc low risk registry"